Spotlight on Internal Medicine
Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events
Start0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: November 23, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
- Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD
Activity Description
In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.
Faculty
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).
Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).
Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 67% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Insmed.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: November 23, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
- Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD
Activity Description
In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.
Faculty
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).
Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).
Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 67% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Insmed.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Internal Medicine Presentations
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 1: Long-Acting Injectables
StartActivity Details
0.25 Contact Hour(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for HIV specialists engaged in the care of patients with HIV.
Learning Objectives
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
- Review recent data on new and emerging ART regimens
Activity Description
Recent advances in antiretroviral therapy have led to the advent of long-acting injectables (LAIs) to treat HIV. Clinicians have many questions about safety, efficacy, and implementation, as well as questions about how best to select and educate patients. Dr. David Malebranche and Dr. Raphael J. Landovitz discuss a patient who may be a candidate for an LAI and address common questions about patient selection and education, oral lead-in, dosing considerations, missed doses, injection site reactions, and clinic protocols.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
Center Co-Director
Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Core Co-Director
CHIPTS Combination Prevention Core
Los Angeles, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
Raphael J. Landovitz, MD, MSC: Consulting Fees: Cepheid, Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for HIV specialists engaged in the care of patients with HIV.
Learning Objectives
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
- Review recent data on new and emerging ART regimens
Activity Description
Recent advances in antiretroviral therapy have led to the advent of long-acting injectables (LAIs) to treat HIV. Clinicians have many questions about safety, efficacy, and implementation, as well as questions about how best to select and educate patients. Dr. David Malebranche and Dr. Raphael J. Landovitz discuss a patient who may be a candidate for an LAI and address common questions about patient selection and education, oral lead-in, dosing considerations, missed doses, injection site reactions, and clinic protocols.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
Center Co-Director
Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Core Co-Director
CHIPTS Combination Prevention Core
Los Angeles, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
Raphael J. Landovitz, MD, MSC: Consulting Fees: Cepheid, Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 2: Adolescents and Young Adults Newly Diagnosed with HIV
StartActivity Details
0.25 Contact Hour(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for HIV specialists engaged in the care of patients with HIV.
Learning Objectives
After completing this activity, the participant should be better able to:
- Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder
Activity Description
Adolescents and young adults newly diagnosed with HIV often necessitate some different management strategies compared with adults. This can range from treatment selection to transitioning from a pediatric clinic to an adult HIV clinic. Many providers who are accustomed to treating adults are not fully prepared for caring for an adolescent patient. Dr. David Malebranche and Dr. David C. Griffith discuss a newly diagnosed adolescent and address common questions about discussing an HIV diagnosis, ART selection and considerations for future adverse events, and educating about adherence, refilling prescriptions, mental health, and transitioning to an adult clinic.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
Medical Director, Clinical Associate
Johns Hopkins AIDS Service County Program
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
David C. Griffith, MD: Consulting Fees: Gilead Sciences, Inc.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
This activity is intended for HIV specialists engaged in the care of patients with HIV.
Learning Objectives
After completing this activity, the participant should be better able to:
- Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder
Activity Description
Adolescents and young adults newly diagnosed with HIV often necessitate some different management strategies compared with adults. This can range from treatment selection to transitioning from a pediatric clinic to an adult HIV clinic. Many providers who are accustomed to treating adults are not fully prepared for caring for an adolescent patient. Dr. David Malebranche and Dr. David C. Griffith discuss a newly diagnosed adolescent and address common questions about discussing an HIV diagnosis, ART selection and considerations for future adverse events, and educating about adherence, refilling prescriptions, mental health, and transitioning to an adult clinic.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
Medical Director, Clinical Associate
Johns Hopkins AIDS Service County Program
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
David C. Griffith, MD: Consulting Fees: Gilead Sciences, Inc.
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment
StartActivity Details
1.0 ABIM MOC Point(s)
Expires: October 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
- Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
- Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.
Activity Description
Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD.
Agenda
Introduction
Culley C. Carson, MD, FACS, FRCS(hon)
The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO
Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG
Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)
Activity Chair
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC
Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals
Faculty
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI
Disclosure: No relevant financial relationships to disclose.
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC
Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity enables the participant to earn up to 1.0 Medical Knowledge MOC
point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Endo Pharmaceuticals Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
Contact us at CME@VindicoCME.com
Activity Details
1.0 ABIM MOC Point(s)
Expires: October 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
- Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
- Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.
Activity Description
Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD.
Agenda
Introduction
Culley C. Carson, MD, FACS, FRCS(hon)
The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO
Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG
Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)
Activity Chair
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC
Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals
Faculty
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI
Disclosure: No relevant financial relationships to disclose.
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC
Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity enables the participant to earn up to 1.0 Medical Knowledge MOC
point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Endo Pharmaceuticals Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
Contact us at CME@VindicoCME.com
Test Your HIV Management Skills Across the Spectrum of Care: From Newly Diagnosed to Aging Patients With HIV
StartActivity Details
1.25 contact hour(s)
Expires: October 28, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Statement of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Target Audience
This activity is intended for infectious disease and HIV specialists related to HIV clinical management skills, with the overall goal of the program to improve the care of patients with HIV.
Educational Objectives
Upon completion of this program, the participant should be better able to:
- Employ appropriate switching strategies in aging patients with multiple comorbidities by considering drug-drug interactions, patient characteristics, patient preference, and risk factors for worsening comorbidities
- Tailor ART regimens for transgender patients with HIV to avoid interactions with gender-affirming hormone therapy, account for patient preference, and improve adherence
- Initiate treatment with ART for all eligible patients as soon as possible following diagnosis of HIV
Program Description
HIV is a rapidly evolving field and treatment decisions must be carefully tailored to each patient to improve their outcomes and their adherence. To best treat their patients, clinicians must be familiar with the nuances of ART selection, drug-drug interactions, switching strategies, and how best to care for the whole patient. This activity will examine an older patient with common comorbidities, such as cardiovascular disease and depression, a transgender woman who is concerned about interactions between her antiretroviral therapy and gender affirming hormones and is unstably housed, and a newly diagnosed man who uses drugs recreationally. This activity of 3 simulated patient cases will allow learners to hear patient/clinician interactions, make treatment decisions for the patient, learn what optimal decisions should be, and review data supporting those choices.
Faculty
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree
from the University of Chicago Pritzker School of Medicine in Illinois before
completing her residency training in internal medicine and pediatrics at
Mount Sinai Medical Center in New York and her infectious disease fellowship
at Stanford University Hospital in California. She also completed a master’s
degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty
at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research
related to HIV with the objective of increasing access to and uptake of
effective HIV treatment and prevention modalities by the most at-risk and
indigent populations. As the principal investigator of the DC MACS/WIHS
Combined Cohort Study, she aims to understand how HIV contributes to
comorbidities, metabolic and cardiovascular complications, and long-term
treatment outcomes, along with social, psychological, and cognitive effects
of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for
almost a decade, including at a tertiary care academic center as well as a
community-based clinic in the ward with highest HIV prevalence in southeast
DC. Most of her US-based research projects are driven by questions that she
identifies in the context of providing care to a highly indigent and socially
vulnerable population.
Associate Professor of Medicine
Divisions of Infectious Diseases and Internal Medicine
Associate Director, Mentored Scholarly Activity
University of Colorado School of Medicine
Associate Director of HIV and Viral Hepatitis Prevention
Denver Health
Denver, Colorado
Dr. Sarah Rowan is the Associate Director of HIV and Viral Hepatitis Prevention at Denver Public Health and Associate Professor in the Divisions of Infectious Diseases and General Internal Medicine at the University of Colorado Denver. She specializes in the care of patients with HIV, hepatitis C, and sexually transmitted infections. Dr. Rowan’s research interests include HIV and hepatitis C testing, epidemiology and engagement in care, as well as HIV and hepatitis C-related health disparities and more recently, COVID-19 testing. She has led several grant-funded initiatives designed to promote HIV and hepatitis C testing and treatment. She also serves as the Associate Director for Public and Community Health for the Mentored Scholarly Activity Program in the University of Colorado School of Medicine.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hour(s).
Instructions to Receive Credit
- Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s) and post-activity evaluation.
- To view the first simulation scenario, launch the simulation from the link provided using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
- Interact appropriately to satisfy each objective to unlock the next objective and view the next simulation scenario.
- The simulation will track your progress until all scenario objectives are complete.
- Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.
- As you complete each scenario (1 minimum, 3 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.25 credits). Click or tap "Credit" to determine your CE credit status.
- Upon successful completion of the evaluation, you can download/print a certificate of credit immediately via the browser.
System Requirements
Any modern phone or tablet with at least 2GB of RAM (typically 3-4 years old or newer), or a PC/Mac that is 5 years old or newer. A good user experience requires a broadband connection of 4G or better via a modern web browser (Chrome, Firefox, Safari, or Edge; Internet Explorer is not supported).
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Seble G. Kassaye, MD, MS
Nothing to disclose
Sarah E. Rowan, MD
Nothing to
disclose
The PIM planners and managers have nothing to disclose. The Integritas
Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Copyright Statement
This CME simulation activity is licensed to Integritas Communications. Copyright © 2021 Syandus Inc and Integritas Communications. All rights reserved. No part of this simulation activity may be reproduced without written permission from Integritas Communications and Syandus Inc.
Activity Details
1.25 contact hour(s)
Expires: October 28, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Statement of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Target Audience
This activity is intended for infectious disease and HIV specialists related to HIV clinical management skills, with the overall goal of the program to improve the care of patients with HIV.
Educational Objectives
Upon completion of this program, the participant should be better able to:
- Employ appropriate switching strategies in aging patients with multiple comorbidities by considering drug-drug interactions, patient characteristics, patient preference, and risk factors for worsening comorbidities
- Tailor ART regimens for transgender patients with HIV to avoid interactions with gender-affirming hormone therapy, account for patient preference, and improve adherence
- Initiate treatment with ART for all eligible patients as soon as possible following diagnosis of HIV
Program Description
HIV is a rapidly evolving field and treatment decisions must be carefully tailored to each patient to improve their outcomes and their adherence. To best treat their patients, clinicians must be familiar with the nuances of ART selection, drug-drug interactions, switching strategies, and how best to care for the whole patient. This activity will examine an older patient with common comorbidities, such as cardiovascular disease and depression, a transgender woman who is concerned about interactions between her antiretroviral therapy and gender affirming hormones and is unstably housed, and a newly diagnosed man who uses drugs recreationally. This activity of 3 simulated patient cases will allow learners to hear patient/clinician interactions, make treatment decisions for the patient, learn what optimal decisions should be, and review data supporting those choices.
Faculty
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia
Dr. Seble Kassaye earned her medical degree
from the University of Chicago Pritzker School of Medicine in Illinois before
completing her residency training in internal medicine and pediatrics at
Mount Sinai Medical Center in New York and her infectious disease fellowship
at Stanford University Hospital in California. She also completed a master’s
degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty
at Georgetown University in December 2012.
Dr. Kassaye’s investigative focus is on clinical and translational research
related to HIV with the objective of increasing access to and uptake of
effective HIV treatment and prevention modalities by the most at-risk and
indigent populations. As the principal investigator of the DC MACS/WIHS
Combined Cohort Study, she aims to understand how HIV contributes to
comorbidities, metabolic and cardiovascular complications, and long-term
treatment outcomes, along with social, psychological, and cognitive effects
of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for
almost a decade, including at a tertiary care academic center as well as a
community-based clinic in the ward with highest HIV prevalence in southeast
DC. Most of her US-based research projects are driven by questions that she
identifies in the context of providing care to a highly indigent and socially
vulnerable population.
Associate Professor of Medicine
Divisions of Infectious Diseases and Internal Medicine
Associate Director, Mentored Scholarly Activity
University of Colorado School of Medicine
Associate Director of HIV and Viral Hepatitis Prevention
Denver Health
Denver, Colorado
Dr. Sarah Rowan is the Associate Director of HIV and Viral Hepatitis Prevention at Denver Public Health and Associate Professor in the Divisions of Infectious Diseases and General Internal Medicine at the University of Colorado Denver. She specializes in the care of patients with HIV, hepatitis C, and sexually transmitted infections. Dr. Rowan’s research interests include HIV and hepatitis C testing, epidemiology and engagement in care, as well as HIV and hepatitis C-related health disparities and more recently, COVID-19 testing. She has led several grant-funded initiatives designed to promote HIV and hepatitis C testing and treatment. She also serves as the Associate Director for Public and Community Health for the Mentored Scholarly Activity Program in the University of Colorado School of Medicine.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Integritas Communications.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the health
care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hour(s).
Instructions to Receive Credit
- Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s) and post-activity evaluation.
- To view the first simulation scenario, launch the simulation from the link provided using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
- Interact appropriately to satisfy each objective to unlock the next objective and view the next simulation scenario.
- The simulation will track your progress until all scenario objectives are complete.
- Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.
- As you complete each scenario (1 minimum, 3 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.25 credits). Click or tap "Credit" to determine your CE credit status.
- Upon successful completion of the evaluation, you can download/print a certificate of credit immediately via the browser.
System Requirements
Any modern phone or tablet with at least 2GB of RAM (typically 3-4 years old or newer), or a PC/Mac that is 5 years old or newer. A good user experience requires a broadband connection of 4G or better via a modern web browser (Chrome, Firefox, Safari, or Edge; Internet Explorer is not supported).
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Seble G. Kassaye, MD, MS
Nothing to disclose
Sarah E. Rowan, MD
Nothing to
disclose
The PIM planners and managers have nothing to disclose. The Integritas
Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Copyright Statement
This CME simulation activity is licensed to Integritas Communications. Copyright © 2021 Syandus Inc and Integritas Communications. All rights reserved. No part of this simulation activity may be reproduced without written permission from Integritas Communications and Syandus Inc.
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠
StartActivity Details
0.75 ABIM MOC Point(s)
Expires: October 28, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
- Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
- Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
- Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting
Activity Description
Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.
Faculty
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology
Chief, Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director, Translational Research
Yale Cancer Center
New Haven, CT
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT
Head, Fingerland Department of Pathology
Charles University, Medical Faculty
Hradec Králové, Czech Republic
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).
Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).
Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical
Education, LLC designates this enduring material for a maximum of 0.75
AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.75 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants will earn MOC points equivalent to the amount of
CME credits claimed for the activity. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of
completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed
by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The
winner will be selected via automated random drawing on a quarterly basis
from among all eligible entries and notified through the contact information
provided. In accordance with our privacy policy, we do not share your
information with any third parties. By entering the sweepstakes, you grant
RMEI permission to use your e-mail address to reach you for notification and
prize fulfillment. Only individuals who complete the evaluation forms and
provide contact information will be eligible to win. Open to those who have a
US postal address and who are 18 years or older. Only one prize per person
and per household will be awarded. The prize will be a $100 Amazon gift
card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.75 ABIM MOC Point(s)
Expires: October 28, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
- Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
- Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
- Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting
Activity Description
Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.
Faculty
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology
Chief, Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director, Translational Research
Yale Cancer Center
New Haven, CT
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT
Head, Fingerland Department of Pathology
Charles University, Medical Faculty
Hradec Králové, Czech Republic
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).
Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).
Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical
Education, LLC designates this enduring material for a maximum of 0.75
AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.75 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants will earn MOC points equivalent to the amount of
CME credits claimed for the activity. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of
completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed
by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The
winner will be selected via automated random drawing on a quarterly basis
from among all eligible entries and notified through the contact information
provided. In accordance with our privacy policy, we do not share your
information with any third parties. By entering the sweepstakes, you grant
RMEI permission to use your e-mail address to reach you for notification and
prize fulfillment. Only individuals who complete the evaluation forms and
provide contact information will be eligible to win. Open to those who have a
US postal address and who are 18 years or older. Only one prize per person
and per household will be awarded. The prize will be a $100 Amazon gift
card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?
StartActivity Details
Expires: October 19, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
- Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
- Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.
Activity Description
In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.
Agenda
Introduction and Immunopathogenesis of COVID-19 – Leonard H.
Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? –
Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB
Faculty
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure:
Ownership Interest: Johnson & Johnson
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH
Disclosure:
Speakers Bureau: Sanofi-Genzyme
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX
Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: October 19, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
- Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
- Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.
Activity Description
In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines.
Agenda
Introduction and Immunopathogenesis of COVID-19 – Leonard H.
Calabrese, DO
Assessing Risk for Disease Progression – Cassandra Calabrese, DO
Managing Patients With Severe COVID-19 Infection: What Do We Know? –
Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentations – Ivan O. Rosas, MD
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB
Faculty
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure:
Ownership Interest: Johnson & Johnson
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH
Disclosure:
Speakers Bureau: Sanofi-Genzyme
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX
Disclosure:
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment
StartActivity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Inflammatory Bowel Disease (IBD) eHealth Source™ Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up To Date? A Focus on Clinical Evidence and Guideline Recommendations
StartActivity Details
Expires: TBD
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Target Audience
The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).
Learning Objectives
After completing this activity, the participant should be better able to:
- Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
- Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
- Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
- Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy
Activity Description
This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.
Statement of Educational Need
The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.
Reference
- Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.
Faculty
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosure of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc.,
Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc.,
Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences,
Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences,
Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research
Support: Pfizer Inc., Prometheus Biosciences, Takeda
Pharmaceuticals U.S.A., Inc.; Honoraria (general):
AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly
and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus
Biosciences; Honoraria (teaching, lecturing, or
speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen
Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda
Pharmaceuticals U.S.A., Inc., UCB S.A.
Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc.,
Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers
Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals,
Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen
Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative
Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis
International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda
Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group;
Grant/Research Support: AbbVie Inc., Janssen
Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock
Shareholder: Intestinal Biotech Development;
Other/Royalty (lectures): AbbVie Inc., Amgen Inc.,
Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals
U.S.A., Inc.
The following planners and managers have no relevant financial relationships with ineligible companies:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
Expires: TBD
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Target Audience
The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).
Learning Objectives
After completing this activity, the participant should be better able to:
- Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
- Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
- Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
- Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy
Activity Description
This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.
Statement of Educational Need
The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.
Reference
- Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.
Faculty
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosure of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc.,
Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc.,
Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences,
Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences,
Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research
Support: Pfizer Inc., Prometheus Biosciences, Takeda
Pharmaceuticals U.S.A., Inc.; Honoraria (general):
AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly
and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus
Biosciences; Honoraria (teaching, lecturing, or
speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen
Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda
Pharmaceuticals U.S.A., Inc., UCB S.A.
Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc.,
Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers
Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals,
Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen
Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative
Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis
International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda
Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group;
Grant/Research Support: AbbVie Inc., Janssen
Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock
Shareholder: Intestinal Biotech Development;
Other/Royalty (lectures): AbbVie Inc., Amgen Inc.,
Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals
U.S.A., Inc.
The following planners and managers have no relevant financial relationships with ineligible companies:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
StartActivity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The Changing Landscape of Immune-Based Therapies for COVID-19
StartActivity Details
Expires: September 28, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the clinical and immunological events underlying the natural history of COVID-19.
- Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
- Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.
Activity Description
The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.
Agenda
Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO
Updates on Immune-Based Therapies for the Management of Patients
With COVID-19
Kevin Winthrop, MD, MPH
Considerations for Outpatient Management of Immunocompromised
Patients
Cassandra Calabrese, DO
Putting it All Together: How Should We Manage Patients
Hospitalized With COVID-19?
D. Clark Files, MD
Conclusion
Leonard H. Calabrese, DO
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB
Faculty
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH
Disclosure:
Speakers Bureau: Sanofi-Genzyme
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC
Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR
Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: September 28, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the clinical and immunological events underlying the natural history of COVID-19.
- Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
- Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.
Activity Description
The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.
Agenda
Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO
Updates on Immune-Based Therapies for the Management of Patients
With COVID-19
Kevin Winthrop, MD, MPH
Considerations for Outpatient Management of Immunocompromised
Patients
Cassandra Calabrese, DO
Putting it All Together: How Should We Manage Patients
Hospitalized With COVID-19?
D. Clark Files, MD
Conclusion
Leonard H. Calabrese, DO
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB
Faculty
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH
Disclosure:
Speakers Bureau: Sanofi-Genzyme
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC
Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR
Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com